China, Sept. 25 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Clinical Study of Polatuzumab Vedotin-Based Combination Regimen for Low-Risk Large B-Cell Lymphoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600133391
Registration Time: 2026/09/24
Type: Interventional study
Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=344628
Published by HT Digital Content Services with permission from Health Daily Digest....